Sastasundar Ventures Valuation

Is SASTASUNDR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SASTASUNDR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SASTASUNDR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SASTASUNDR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SASTASUNDR?

Key metric: As SASTASUNDR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SASTASUNDR. This is calculated by dividing SASTASUNDR's market cap by their current revenue.
What is SASTASUNDR's PS Ratio?
PS Ratio	0.8x
Sales	₹13.09b
Market Cap	₹9.77b

SASTASUNDR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	16.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SASTASUNDR's PS Ratio compare to its peers?

The above table shows the PS ratio for SASTASUNDR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.2x
DENTALKART Vasa Denticity	6.2x	n/a	₹12.8b
REMUS Remus Pharmaceuticals	3.4x	n/a	₹15.6b
BALAXI Balaxi Pharmaceuticals	1.6x	n/a	₹4.1b
QMSMEDI QMS Medical Allied Services	1.5x	n/a	₹2.0b
SASTASUNDR Sastasundar Ventures	0.8x	24.3%	₹10.2b

Price-To-Sales vs Peers: SASTASUNDR is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (3.2x).

Price to Sales Ratio vs Industry

How does SASTASUNDR's PS Ratio compare vs other companies in the IN Healthcare Industry?

9 Companies	Price / Sales	Estimated Growth	Market Cap
MONOPHARMA Mono Pharmacare	0.5x	n/a	US$7.71m
539938 Medico Intercontinental	0.7x	n/a	US$6.76m
542934 Chandra Bhagat Pharma	0.3x	n/a	US$6.15m
530697 Zenlabs Ethica	0.5x	n/a	US$3.14m

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SASTASUNDR is good value based on its Price-To-Sales Ratio (0.8x) compared to the Indian Healthcare industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is SASTASUNDR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SASTASUNDR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.8x
Fair PS Ratio	1.6x

Price-To-Sales vs Fair Ratio: SASTASUNDR is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Mohini Health & Hygiene

₹916.4m

Engages in the manufacture and sale of health and hygiene products in India.

MHHL

₹50.25

2.6%

-29.7%

Dr Lalchandani Labs

₹73.6m

Provides diagnostic and related healthcare tests and services in India.

541299

₹18.45

2.5%

n/a

N G Industries

₹573.9m

Provides various healthcare services in India.

530897

₹171.30

2.3%

3.0%